louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03108690: Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia
Official title: Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Bacteremia
Keywords: Therapeutic drug monitoring
Continuous infusion
Beta-lactam
Antibiotics
Bacteraemia
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2017-04-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The study investigates whether Therapeutic Drug Monitoring (TDM) and continuous infusion (CI) of beta-lactam antibiotics optimises target concentrations in patients with bacteraemia.


Eligibility criteria: Inclusion Criteria:

* Have a positive blood culture.
* Undergo treatment with either intravenous penicillin, ampicillin, piperacillin/tazobactam, dicloxacillin, cefuroxime or meropenem.
* Hospitalised at Hvidovre University Hospital.
* Age ≥ 18.
* Able to understand and give informed consent.
* Included in the study within 24 hours after the final positive blood culture answer.

Exclusion Criteria:

* Positive blood culture is interpreted as contamination.
* The patient dies before the intervention.

Primary outcomes:
measure: Target concentrations.
timeFrame: 30 days after intervention.
Secondary outcomes:
measure: Morbidity.
timeFrame: 30 days after intervention.
measure: Number of days until medically discharged.
timeFrame: 30 days after intervention.
measure: Failed antibiotic treatments.
timeFrame: 30 days after intervention.
measure: Amount of antibiotic used.
timeFrame: 30 days after intervention.
measure: Antibiotic side effects and complications.
timeFrame: 30 days after intervention.
measure: Mortality.
timeFrame: 30 days after intervention.
measure: Number of participants with abnormal clinical data and/or abnormal laboratory values.
timeFrame: 30 days after intervention.
Other outcomes:
Locations:
Study officials:
affiliation: Hvidovre University Hospital
name: Sara Thønnings, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04799990: Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
Official title: Post-Marketing Real World Safety Study of Risankizumab in the United States
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Psoriasis
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2021-03-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study is not recruiting and using secondary data sources only

Brief summary: Study is not recruiting and using secondary data sources only

Detailed description: Study is not recruiting and using secondary data sources only

Eligibility criteria: Study is not recruiting and using secondary data sources only

Primary outcomes:
measure: Incidence Rate of Participants With Major Adverse Cardiovascular Events (MACE)
timeFrame: Up to approximately 10 years
Secondary outcomes:
measure: Incidence Rate of Participants With Serious Infections
timeFrame: Up to approximately 10 years
measure: Incidence Rate of Participants With Tuberculosis
timeFrame: Up to approximately 10 years
measure: Incidence Rate of Participants With Opportunistic Infections Excluding Tuberculosis and Herpes Zoster
timeFrame: Up to approximately 10 years
measure: Incidence Rate of Participants With Serious Hypersensitivity Reactions
timeFrame: Up to approximately 10 years
measure: Incidence Rate of Participants With Autoimmune Disease
timeFrame: Up to approximately 10 years
measure: Incidence Rate of Participants With Neurologic or Demyelinating Disease
timeFrame: Up to approximately 10 years
measure: Incidence Rate of Participants With Gastrointestinal Adverse Events
timeFrame: Up to approximately 10 years
measure: Incidence Rate of Participants With Nonmalignant-Hematologic Adverse Events
timeFrame: Up to approximately 10 years
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: ABBVIE INC.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02254590: Irrigation Endoscopic Decompression
Official title: Irrigation Endoscopic Decompressive Laminotomy. A New Endoscopic Approach for Spinal Stenosis Decompression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lumbar Spinal Canal Stenosis
Keywords: IEDL
irrigation endoscopic decompressive laminotomy
irrigation endoscopic decompression
minimally invasive spine surgery
endoscopic decompression
spinal stenosis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2014-10-02
Enrollment: 104
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate a new endoscopic technique for lumbar spinal canal decompression.

Detailed description: 104 consecutive patients suffering of neurogenic claudication were included in the study.

Patients were operated using the irrigation endoscopic decompression technique. Mean Follow up was 28 months Primary outcome measures were assessed using the Oswestry Disability Index \[19\] and the modified Macnab Criteria All statistical calculations were done using computer programs SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows

Eligibility criteria: Inclusion Criteria:

1. Neurogenic claudication or radicular leg pain with or without back pain, and/or a neurological deficit
2. Symptoms and signs correlating with moderate to severe spinal canal stenosis as shown on MRI. (Degenerative and congenital bony stenosis were included)
3. Failure of 3 months conservative treatment
4. Grade I degenerative spondylolisthesis and degenerative scoliosis

Exclusion Criteria:

1. Segmental Instability
2. Lytic Spondylolisthesis

2- Predominant low back pain

Primary outcomes:
measure: Oswestry Disability Index
timeFrame: 24 months
measure: Modified Macnab criteria
timeFrame: 24 months
Secondary outcomes:
measure: Time for ambulation
timeFrame: 72 hours
measure: Time for hospitalization
timeFrame: 72 hours
measure: VAS for back pain
timeFrame: 72 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02833090: The Plasma Serotonin and Aortic Stenosis: a Pilot Study.
Official title: The Plasma Serotonin and Aortic Stenosis: a Pilot Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aortic Stenosis
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2016-07-14
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this study is to describe the increase in plasma serotonin or 5-hydroxytryptamine (5-HT) in patient with increased severity of aortic stenosis and increased weight cardiac muscle.

Detailed description: Calcific aortic stenosis is the most frequent valve disease in adults. Without therapeutic strategy, this disease leads to heart failure and death. Surgical aortic valve replacement is now a well tolerated cardiac surgery leading to excellent outcomes. Until recently, calcific aortic stenosis was considered to be histopathologically degenerative or passive in origin. It is now recognized, however, as a complex cellular process with features of atherosclerosis. It has been observed that drugs may slow dawn the progression of aortic stenosis in observational studies.

It has been suggested that serotonin, a monoamine neurotransmitter and a peripheral signal mediator, may be involved in the progression of aortic stenosis and also in its consequences on myocardium hypertrophy.

In the blood, serotonin in mainly stored in platelets, which release serotonin involved in post-injury vasoconstriction, thrombus formation, fibrosis and atherogenesis.

This study hypothesized those patients with aortic stenosis exhibit higher circulating serotonin levels than their counterparts without heart disease. In addition to circulating serotonin, its metabolite 5-HIAA will be systematically measured on all patients.

This study would allow to determine the potential of plasma serotonin as a prognosis marker and perhaps suggest the discovery of new targets for treatment of aortic stenosis.

Eligibility criteria: Inclusion Criteria:

* Group 1 : non aortic stenosis
* Goup 2, 3 and 4 : aortic stenosis

Exclusion Criteria:

-

Primary outcomes:
measure: Measurements of 5-HT
timeFrame: baseline
Secondary outcomes:
measure: Measurements of acide 5-hydroxy-indol-acetic (5-HIAA)
timeFrame: Baseline
measure: Arterial platelet activation
timeFrame: Baseline
Other outcomes:
Locations:
city: Toulouse
country: France
facility: University Hospital
Study officials:
affiliation: University Hospital, Toulouse
name: Olivier Lairez, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rouzaud-Laborde C, Delmas C, Pizzinat N, Tortosa F, Garcia C, Mialet-Perez J, Payrastre B, Sie P, Spreux-Varoquaux O, Sallerin B, Carrie D, Galinier M, Parini A, Lairez O. Platelet activation and arterial peripheral serotonin turnover in cardiac remodeling associated to aortic stenosis. Am J Hematol. 2015 Jan;90(1):15-9. doi: 10.1002/ajh.23855.
Clinical trial NCT00922090: A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended
Official title: A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended-Release Tablets (SEROQUEL XRâ) in Subjects With Schizophrenia-An Observational, Multicentric Prospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Keywords: Schizophrenia
Seroquel XR
CGI-CB
SWN-K
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-06-17
Enrollment: 1494
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult diagnosed as Schizophrenia according to DSM-IV-TR criteria, the groups will be selected selected from general hospital or mental hospital.

Brief summary: The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.


Eligibility criteria: Inclusion Criteria:

* Diagnosed as Schizophrenia according to DSM-IV-TR criteria
* Patients who are taking Seroquel XR no longer than 1 month
* Patients who get antipsychotics monotherapy at least 1 week before enroll in this study

Exclusion Criteria:

* First episode, drug naive schizophrenic subjects.
* Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I diagnosis,concomitant organic mental disorder or mental retardation that in the opinion of the Principal Investigator may interfere with study conduct or interpretation.
* Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrollment.

Primary outcomes:
measure: Change from baseline of the Clinical Global Impression score - Clinical Benefit Scale (CGI-CB) after 2 months of treatment with Seroquel XR
timeFrame: 8 weeks
Secondary outcomes:
measure: CGI-I score's change from 7th day to 8weeks
timeFrame: 8 weeks
measure: Patients' ratio who've been improved CGI-S score more than 4, from baseline to 8weeks
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Research Site
city: Daegu
country: Korea, Republic of
facility: Research Site
city: Goyang
country: Korea, Republic of
facility: Research Site
city: Gwangju
country: Korea, Republic of
facility: Research Site
city: Incheon
country: Korea, Republic of
facility: Research Site
city: Jeju
country: Korea, Republic of
facility: Research Site
city: Kyung gi
country: Korea, Republic of
facility: Research Site
city: Kyungju
country: Korea, Republic of
facility: Research Site
city: Kyungnam
country: Korea, Republic of
facility: Research Site
city: Namyangju
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
Study officials:
affiliation: AstraZeneca Korea
name: JoonWoo Bahn, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05214690: A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
Official title: A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW1809-T2 and DW1809-1 in Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Osteoarthritis
Rheumatoid Arthritis
Back Pain
Acute Upper Respiratory Tract Infection
Lead sponsor: Daewon Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2022-01-31
Enrollment: 37
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study


Eligibility criteria: Inclusion Criteria:

* Healthy Volunteers who are ≥19 years old
* Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2 and

Exclusion Criteria:

* Clinically significant Medical History
* In the case of women, pregnant(Urine-HCG positive) or lactating women

Primary outcomes:
measure: Peak Plasma Concentration (Cmax)
timeFrame: up to 8 hour
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: up to 8 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Cheongju-si
country: Korea, Republic of
facility: Chungbuk National University Hospital
Study officials:
References:
Clinical trial NCT01595490: Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza
Official title: A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Posttraumatic Stress Disorder
Lead sponsor: The Center for Mind-Body Medicine
Sponsor class: OTHER
Collaborators: name: The Atlantic Philanthropies
First posted: 2012-05-10
Enrollment: 121
Sex: ALL
Minimum age (years): 14
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to determine whether participation in a mind-body skills program by war-traumatized adolescents in Gaza will result in improvement of posttraumatic stress symptoms, depression, and levels of aggression compared to a control group.


Eligibility criteria: Inclusion Criteria:

* having experienced a political violence or war-related criterion A stressor
* meeting the American Psychiatric Association (DSM-IV-TR) criteria for PTSD according to screening scores on the Child PTSD Symptom Scale

Exclusion Criteria:

* former psychosocial or medical treatment for mental health conditions
* significant cognitive impairment

Primary outcomes:
measure: Child PTSD Symptom Scale
timeFrame: Change from Baseline (Week 1) at 6 weeks
measure: Child PTSD Symptom Scale
timeFrame: Change from Week 6 at 18 weeks
measure: Child PTSD Symptom Scale
timeFrame: Change from Baseline (Week 1) at 18 weeks
Secondary outcomes:
measure: Children's Depression Inventory -2 Short Form
timeFrame: Change from Baseline (Week 1) at 6 weeks
measure: Children's Depression Inventory -2 Short Form
timeFrame: Change from Week 6 at 18 weeks
measure: Children's Depression Inventory -2 Short Form
timeFrame: Change from Baseline (Week 1) at 18 weeks
measure: Aggression Questionnaire
timeFrame: Change from Baseline (Week 1) at 6 weeks
measure: Aggression Questionnaire
timeFrame: Change from Week 6 at 18 weeks
measure: Aggression Questionnaire
timeFrame: Change from Baseline (Week 1) at 18 weeks
Other outcomes:
Locations:
city: Gaza City
country: Israel
facility: The Center for MInd-Body Medicine
state: Palestine
Study officials:
affiliation: The Center for Mind-Body Medicine
name: James S Gordon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02062190: Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia
Official title: Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Schizophrenia
Lead sponsor: Federal University of Rio Grande do Sul
Sponsor class: OTHER
Collaborators: name: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
First posted: 2014-02-13
Enrollment: 19
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?

Detailed description: Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.

Eligibility criteria: Inclusion Criteria:

Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which are in clozapine medication for at least 6 months.

Exclusion Criteria:

Patients will be excluded from the study:

* Have a diagnosis of diabetes
* Use other antipsychotic drugs, clozapine beyond
* Using medicines for diabetes or dyslipidaemia
* Accept not participate in any stage of the research.

Primary outcomes:
measure: Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels.
timeFrame: 1 month
Secondary outcomes:
measure: Cognitive performance will be assessed with a battery of cognitive tests and BPRS (brief psychiatric rating scale) to assess symptoms.
timeFrame: 1 month
Other outcomes:
measure: Nutritional evaluation will be conducted by anthropometric data and food intake by 24-hour Recall Survey.
timeFrame: 1 month
Locations:
city: Porto Alegre
country: Brazil
facility: HCPA
state: RS
Study officials:
References:
citation: Zortea K, Franco VC, Francesconi LP, Cereser KM, Lobato MI, Belmonte-de-Abreu PS. Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors. Nutrients. 2016 Jan 29;8(2):73. doi: 10.3390/nu8020073.
Clinical trial NCT01923090: Finasteride, Dutasteride and Insulin Action
Official title: An Open Label Study of 5α-reductase Inhibition on the Regulation of Insulin Action and Metabolic Phenotype in Healthy Volunteers.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Healthy Volunteers
Lead sponsor: University of Birmingham
Sponsor class: OTHER
First posted: 2013-08-14
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if an enzyme in the body (5-alpha reductase, 5αR) is important in controlling how the body handles sugar and fat. The investigators believe that 5αR is a crucial step in regulating these actions as well as controlling how insulin works in the body but regulating the amount of steroid hormones including cortisol and testosterone in the body. In previous clinical studies, the investigators have shown that the activity of 5αR increases as you gain weight and decreases with weight loss. In addition, work that the investigators have performed in the laboratory has shown that if you increase 5αR levels in liver cell grown in the laboratory, the amount of fat that they contain increases. The investigators would therefore like to demonstrate the effect of inhibition 5αR on the regulation of insulin, glucose and fat in the body.


Eligibility criteria: Inclusion Criteria:

* Male sex
* Age 18-65years
* BMI 20-35kg/m2
* BMI \>35kg/m2

Exclusion Criteria:

* Diabetes Mellitus
* Glucocorticoid use within the last 6 months
* Uncontrolled hypertension (BP\>160/100mmHg)
* Drugs know to impact upon glucocorticoid metabolism

Primary outcomes:
measure: insulin sensitivity
timeFrame: 3 weeks
Secondary outcomes:
measure: adipose tissue insulin sensitivity
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital
state: West Midlands
Study officials:
References:
Clinical trial NCT04953390: Evaluating Benefits of Hearing Aid Microphone Directionality Technologies
Official title: Evaluating Benefits of Hearing Aid Microphone Directionality Technologies on Spatial Awareness and Speech Intelligibility
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss
Lead sponsor: Sonova AG
Sponsor class: INDUSTRY
First posted: 2021-07-08
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A single group of participants will be evaluating different directional microphone settings on commercially available hearing aids
Primary purpose: TREATMENT

Brief summary: This study will evaluate the impact of hearing aid microphone directionality technologies and settings on speech understanding in noise for experienced hearing aid users. It will also evaluate the participant's spatial awareness of sounds using these different hearing aid microphone directionality technologies.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* experienced hearing aid users
* moderate to moderate severe sensorineural symmetrical hearing loss defined as a difference of less than 10 dB between ears
* must be able to use app and smart phone

Exclusion Criteria:

* asymmetrical hearing losses
* unable or unwilling to use app and smart phone

Primary outcomes:
measure: Subjective Description of DIR1, DIR2, and DIR3 in Controlled Soft Noise Environment
timeFrame: Third appointment (day 28 of study)
measure: Subjective Description of DIR1, DIR2, and DIR3 in Controlled Loud Noise Environment
timeFrame: Third appointment (day 28 of study)
measure: Subjective Preference DIR1, DIR2, and DIR3 in Controlled Soft Noise Environments
timeFrame: Third appointment (day 28 of study)
measure: Subjective Preference DIR1, DIR2, and DIR3 in Controlled Loud Noise Environments
timeFrame: Third appointment (day 28 of study)
Secondary outcomes:
measure: Speech Reception Threshold
timeFrame: 2nd appointment (Day 14 of study)
measure: Observations and Ratings of Satisfaction of Microphone Directionality in Real Life
timeFrame: 4 weeks
measure: Subjective Ratings of Transition Speed From One Directional Microphone Setting to Another Directional Setting
timeFrame: Third appointment (day 28 of study)
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Sonova
state: Illinois
Study officials:
affiliation: Sonova AG
name: Kevin Seitz-Paquette, AuD
role: PRINCIPAL_INVESTIGATOR
References: